1-4 of 4
Arthur Gil
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Andreas Hochhaus, MD, Andreas Burchert, MD, Susanne Saussele, MD, Gabriela M Baerlocher, MD, Tim H Brümmendorf, MD, Paul La Rosée, MD, Dominik Heim, MD, Stefan W Krause, MD, Philipp D le Coutre, MD, Dietger Niederwieser, MD, Thoralf Lange, MD, Alice Fabarius, PhD, Mathias Hänel, MD, Frank Stegelmann, MD, Jiri Mayer, MD, Arthur Gil, MPH, Danny Himsel, MSc, Joerg Hasford, MD, Rüdiger Hehlmann, MD, Thomas Ernst, MD, Christian Fabisch, Dr.rer.MDc., Markus Pfirrmann, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 495.
https://doi.org/10.1182/blood-2019-130043
Published: 2019
Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL+ Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study

Andreas Hochhaus, MD, Susanne Saussele, MD, Gabriela M Baerlocher, Tim H Brümmendorf, MD, Andreas Burchert, MD, Paul La Rosée, MD, Joerg Hasford, MD, Rüdiger Hehlmann, MD, Dominik Heim, MD, Stefan W Krause, MD, Philipp le Coutre, MD, Dietger Niederwieser, MD, Jiří Mayer, Thoralf Lange, MD, Mathias Haenel, MD, Frank Stegelmann, MD, Arthur Gil, MPH, Thomas Ernst, Christian Fabisch, PhD, Markus Pfirrmann, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 460.
https://doi.org/10.1182/blood-2018-99-112119
Published: 2018
Journal Articles

Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608

Thoralf Lange, MD, Rainer Krahl, PhD, Ulrich von Grünhagen, MD, Haifa Kathrin Al-Ali, Schwarzer Andreas, MD, Kathleen Jentsch-Ulrich, MD, Claudia Spohn, MD, Volker Lakner, MD, Michael Assmann, MD, Christian Junghanss, MD, Markus Pfirrmann, Arthur Gil, PhD, Rüdiger Hehlmann, MD, Michael W. Deininger, MD PhD, Dietger Niederwieser, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1615.
https://doi.org/10.1182/blood.V130.Suppl_1.1615.1615
Published: 2017
Journal Articles

Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials

Susanne Saussele, Mareike Stein, Arthur Gil, Ute Kossak-Roth, Michael Lauseker, PhD, Ulrike Proetel, Hermann Einsele, MD, Philippe Schafhausen, Elisabeth Lange, Mathias Hänel, Karsten Spiekermann, MD, Martin Sökler, MD, Clemens Wendtner, Stephan Kremers, Michael Pfreundschuh, Ernst Holler, Wolf-Karsten Hofmann, Andreas Hochhaus, MD, Martin C. Müller, Ruediger Hehlmann, MD, Markus Pfirrmann
Journal: Blood
Blood (2015) 126 (23): 2773.
https://doi.org/10.1182/blood.V126.23.2773.2773
Published: 2015